Skip to main content
main-content

Hematologic cancers

medwireNews coverage from the ASCO Annual Meeting 2018

01-06-2018 | Acute lymphoblastic leukemia | ASCO 2018 | News

Adding nelarabine plus escalating methotrexate boosts pediatric, young adult T-ALL outcomes

The addition of nelarabine and an escalating dose of methotrexate to a standard chemotherapy regimen has achieved the best ever survival outcomes for children and young adults with a new diagnosis of T-cell acute lymphoblastic leukemia who are at risk for recurrence, researchers say.

Source:

ASCO Annual Meeting 2018; Chicago, Illinois, USA

03-06-2018 | B-cell lymphoma | ASCO 2018 | News

News in brief

Ibrutinib, rituximab duo boosts Waldenström macroglobulinemia outcomes

Treatment with the combination of ibrutinib and rituximab results in better outcomes for patients with newly diagnosed or recurrent Waldenström macroglobulinemia than rituximab alone, phase III trial findings indicate.

05-06-2018 | Acute myeloid leukemia | ASCO 2018 | News

Ivosidenib gives encouraging results in IDH1-mutated high-risk AML

Ivosidenib induces durable remission in nearly a third of patients with isocitrate dehydrogenase 1-mutated relapsed or refractory acute myeloid leukemia, phase 1 study data show.

Source:

N Engl J Med 2018; Advance online publication

04-06-2018 | Multiple myeloma | ASCO 2018 | News

Once-weekly carfilzomib shows favorable results for multiple myeloma

Once-weekly treatment with carfilzomib at the maximum tolerated dose significantly delays disease progression compared with twice-weekly treatment at a lower dose in patients with relapsed or refractory multiple myeloma, study data show.

Source:

ASCO Annual Meeting 2018; Chicago, Illinois, USA​​​​​​​, Lancet Oncol 2018; Advance online publication

image credits